Medicine
Famotidine 40 mg/5 mL powder for oral suspension
Famotidine 40 mg/5 mL powder for oral suspension is a generic prescription medicine for oral use, made by 21 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Protect from freezing. Store famotidine for oral suspension dry powder and…
Key facts
- Active ingredient (INN)
- Famotidine
- Brand
- Sold under the generic name
- Strength
- 40 mg/5 mL
- Dosage form
- Powder for oral suspension
- Route
- Oral
- Packs
- 50 mL, 55 mL, 100 mL and 23 more
- Manufacturers
- LupinIndiaAjanta PharmaIndiaAscend LaboratoriesIndiaAurobindo PharmaIndiaBioconIndiaCamber PharmaceuticalsIndiaDr. Reddy's LaboratoriesIndiaMicro LabsIndiaNovadoz PharmaceuticalsIndiaZydus LifesciencesIndia
- Origin register
- US FDA, United States
- Storage
- Protect from freezing. Store famotidine for oral suspension dry powder and constituted suspension at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A02BA03 Famotidine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 29 June 2010
- Identifiers
- RxCUI 310274DailyMed set ID 45df5fae-b28a-4b48-95ef-96e4faad883f, a88e7069-230c-4105-ade0-a98968e18671, c013654e-9cad-4c59-8fea-b00ae1567c18 +21NDC 80005-119, 27241-249, 64980-737 +21Application ANDA217137, ANDA217529, ANDA217655 +12
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 50 mL in 1 bottle | 43386-500-11 | LupinIndia | 17 December 2012 |
| 50 mL in 1 bottle | 68180-150-01 | LupinIndia | 29 June 2010 |
| 50 mL in 1 bottle | 27241-249-49 | Ajanta PharmaIndia | 25 April 2022 |
| 50 mL in 1 bottle | 67877-775-89 | Ascend LaboratoriesIndia | 24 August 2023 |
| 50 mL in 1 bottle | 59651-701-50 | Aurobindo PharmaIndia | 9 July 2025 |
| 50 mL in 1 bottle | 70377-113-11 | BioconIndia | 1 September 2023 |
| 50 mL in 1 bottle | 31722-063-31 | Camber PharmaceuticalsIndia | 17 August 2023 |
| 50 mL in 1 bottle | 43598-572-11 | Dr. Reddy's LaboratoriesIndia | 15 March 2024 |
| 50 mL in 1 bottle | 42571-433-45 | Micro LabsIndia | 1 December 2023 |
| 55 mL in 1 bottle | 72205-233-84 | Novadoz PharmaceuticalsIndia | 16 August 2025 |
| 50 mL in 1 bottle, plastic | 68382-444-05 | Zydus LifesciencesIndia | 22 April 2021 |
| 50 mL in 1 bottle | 60219-2090-4 | Amneal Pharmaceuticals NY | 13 May 2024 |
| 50 mL in 1 bottle | 69238-2090-4 | Amneal Pharmaceuticals NY | 5 August 2022 |
| 50 mL in 1 bottle | 70954-316-10 | ANI Pharmaceuticals | 20 April 2021 |
| 50 mL in 1 bottle | 80005-119-16 | Carnegie Pharmaceuticals | 10 August 2023 |
| 55 mL in 1 bottle | 0527-5190-80 | Lannett | 2 June 2025 |
| 50 mL in 1 bottle, plastic | 68475-400-01 | Navinta | 22 April 2021 |
| 50 mL in 1 bottle | 64980-737-50 | Rising Pharma Holdings | 20 August 2026 |
| 100 mL in 1 bottle | 0832-6045-10 | Upsher-Smith Laboratories | 27 October 2023 |
| 150 mL in 1 bottle | 0832-6045-15 | Upsher-Smith Laboratories | 27 October 2023 |
| 50 mL in 1 bottle | 0832-6045-50 | Upsher-Smith Laboratories | 11 July 2023 |
| 50 mL in 1 bottle | 72603-171-01 | NorthStar Rx | 7 September 2023 |
| 50 mL in 1 bottle | 72603-564-01 | NorthStar Rx | 1 October 2026 |
| 50 mL in 1 bottle | 72162-2599-2 | Bryant Ranch Prepack | 9 January 2026 |
| 50 mL in 1 bottle | 51407-452-50 | Golden State Medical Supply | 19 May 2021 |
| 50 mL in 1 bottle | 81033-023-50 | Kesin Pharma | 25 November 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 15 October 1986 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Famotidine
Clinical summary
Famotidine is a histamine-2 receptor antagonist indicated in hospitalized adults, or as an alternative to oral famotidine in adults, for the treatment of active duodenal ulcer (DU), among other approved uses. MedsAcross supplies Famotidine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about FamotidineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Famotidine prescribing information (Sagent Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Famotidine 40 mg/5 mL powder for oral suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.